
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4B66D8AF3BDB305B66D002D1E25C2.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="transmed">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366063/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Translational Medicine">
<meta name="citation_title" content="Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies">
<meta name="citation_author" content="Belén Sierro-Martínez">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Beatriz Guijarro-Albaladejo">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Ricardo Fernández-Cisnal">
<meta name="citation_author_institution" content="Instituto de Investigación E Innovación Biomédica (INiBICA), Cádiz, Spain">
<meta name="citation_author" content="Alfonso Rodríguez-Gil">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Paola Hernández-Díaz">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="María de la Rosa-Garrido">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Inmaculada Carrasco-Brocal">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Maribel Lara-Chica">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Virginia Escamilla-Gómez">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Raquel Muñoz-García">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Ángela Bella">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Francisco Jose García-Cózar">
<meta name="citation_author_institution" content="Instituto de Investigación E Innovación Biomédica (INiBICA), Cádiz, Spain">
<meta name="citation_author" content="Jose Antonio Pérez-Simón">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_author" content="Estefanía García-Guerrero">
<meta name="citation_author_institution" content="Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="23">
<meta name="citation_firstpage" content="942">
<meta name="citation_doi" content="10.1186/s12967-025-06899-0">
<meta name="citation_pmid" content="40830482">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366063/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366063/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366063/pdf/12967_2025_Article_6899.pdf">
<meta name="description" content="Despite the promising results of CAR-T cell therapy, still a significant proportion of patients experience treatment failure due to absence of response, progression or treatment-related toxicities. Our research aims to investigate how the CAR-T cell ...">
<meta name="og:title" content="Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Despite the promising results of CAR-T cell therapy, still a significant proportion of patients experience treatment failure due to absence of response, progression or treatment-related toxicities. Our research aims to investigate how the CAR-T cell ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366063/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12366063">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12967-025-06899-0"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12967_2025_Article_6899.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366063%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12366063/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12366063/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366063/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-transmed.png" alt="Journal of Translational Medicine logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Translational Medicine" title="Link to Journal of Translational Medicine" shape="default" href="https://translational-medicine.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Transl Med</button></div>. 2025 Aug 19;23:942. doi: <a href="https://doi.org/10.1186/s12967-025-06899-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12967-025-06899-0</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Transl%20Med%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Transl%20Med%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Transl%20Med%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Transl%20Med%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sierro-Mart%C3%ADnez%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Belén Sierro-Martínez</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Belén Sierro-Martínez</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sierro-Mart%C3%ADnez%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Belén Sierro-Martínez</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guijarro-Albaladejo%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Beatriz Guijarro-Albaladejo</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Beatriz Guijarro-Albaladejo</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guijarro-Albaladejo%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Beatriz Guijarro-Albaladejo</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fern%C3%A1ndez-Cisnal%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Ricardo Fernández-Cisnal</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Ricardo Fernández-Cisnal</span></h3>
<div class="p">
<sup>2</sup>Instituto de Investigación E Innovación Biomédica (INiBICA), Cádiz, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fern%C3%A1ndez-Cisnal%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ricardo Fernández-Cisnal</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rodr%C3%ADguez-Gil%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Alfonso Rodríguez-Gil</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Alfonso Rodríguez-Gil</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rodr%C3%ADguez-Gil%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alfonso Rodríguez-Gil</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hern%C3%A1ndez-D%C3%ADaz%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Paola Hernández-Díaz</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Paola Hernández-Díaz</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hern%C3%A1ndez-D%C3%ADaz%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Paola Hernández-Díaz</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20la%20Rosa-Garrido%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">María de la Rosa-Garrido</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">María de la Rosa-Garrido</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22de%20la%20Rosa-Garrido%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">María de la Rosa-Garrido</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Carrasco-Brocal%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Inmaculada Carrasco-Brocal</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Inmaculada Carrasco-Brocal</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Carrasco-Brocal%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Inmaculada Carrasco-Brocal</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lara-Chica%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Maribel Lara-Chica</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Maribel Lara-Chica</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lara-Chica%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maribel Lara-Chica</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Escamilla-G%C3%B3mez%20V%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Virginia Escamilla-Gómez</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Virginia Escamilla-Gómez</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Escamilla-G%C3%B3mez%20V%22%5BAuthor%5D" class="usa-link"><span class="name western">Virginia Escamilla-Gómez</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mu%C3%B1oz-Garc%C3%ADa%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Raquel Muñoz-García</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Raquel Muñoz-García</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mu%C3%B1oz-Garc%C3%ADa%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Raquel Muñoz-García</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bella%20%C3%81%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Ángela Bella</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Ángela Bella</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bella%20%C3%81%22%5BAuthor%5D" class="usa-link"><span class="name western">Ángela Bella</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garc%C3%ADa-C%C3%B3zar%20FJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Francisco Jose García-Cózar</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Francisco Jose García-Cózar</span></h3>
<div class="p">
<sup>2</sup>Instituto de Investigación E Innovación Biomédica (INiBICA), Cádiz, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garc%C3%ADa-C%C3%B3zar%20FJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Francisco Jose García-Cózar</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22P%C3%A9rez-Sim%C3%B3n%20JA%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Jose Antonio Pérez-Simón</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Jose Antonio Pérez-Simón</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22P%C3%A9rez-Sim%C3%B3n%20JA%22%5BAuthor%5D" class="usa-link"><span class="name western">Jose Antonio Pérez-Simón</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garc%C3%ADa-Guerrero%20E%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Estefanía García-Guerrero</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Estefanía García-Guerrero</span></h3>
<div class="p">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Garc%C3%ADa-Guerrero%20E%22%5BAuthor%5D" class="usa-link"><span class="name western">Estefanía García-Guerrero</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain </div>
<div id="Aff2">
<sup>2</sup>Instituto de Investigación E Innovación Biomédica (INiBICA), Cádiz, Spain </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Apr 7; Accepted 2025 Jul 15; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12366063  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830482/" class="usa-link">40830482</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Despite the promising results of CAR-T cell therapy, still a significant proportion of patients experience treatment failure due to absence of response, progression or treatment-related toxicities. Our research aims to investigate how the CAR-T cell product characteristics and particularly the percentage of CAR-negative cells present in the infusion product affects its efficacy and safety.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">CAR-positive (CAR-pos) and CAR-negative (CAR-neg) cells were analyzed during in vitro expansion with IL-2 or IL-7/IL-15. FACS-sorted populations were assessed for cytotoxic effect and secretion of cytokines. Transcriptomic analyses were conducted for CAR-pos and CAR-neg populations.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">A significant reduction in the percentage of transduced (CAR-pos) T cells was observed throughout the in vitro cell culture, where CAR-neg T cells displayed greater expansion along the procedure compared to CAR-pos T cells, using either IL-2 or IL-7/IL-15. CAR-pos T cells exhibited increased expression of activation and exhaustion markers. Comparative analyses of CAR-pos and CAR-neg showed an increased cytotoxic effect in purified samples with 100% CAR-pos T cells compared to non-purified product. Quantification of cytokine levels revealed a significant decrease in IL-6 in purified compared to non-purified products. RNA sequencing analysis revealed significant differential gene expression profile between CAR-pos and CAR-neg cells, the prior exhibiting an upregulation of genes associated with immune checkpoint regulation, cytokine-cytokine receptor interaction and Th1/Th2 and Th17 cell differentiation pathways.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">CAR-neg T cells exhibit a significantly greater expansion compared to CAR-pos T cells alongside CAR-T cell production. The percentage of CAR-neg cells influences the specific cytotoxicity of the product and on the cytokine pattern, which might influence both efficacy and toxicity and, therefore, the number of CAR-neg T cells within the infusion product must be considered in the clinical setting. Purification of CAR-pos T cells could potentially optimize product characteristics.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s12967-025-06899-0.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> CAR-T, FACS-sorting, CAR-negative, RNA-seq, ICANS, CRS, IL-6</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par28">Chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer immunotherapy, achieving remarkable remission rates in relapsed/refractory (R/R) hematological malignancies. The 2017 FDA approval of the first two commercial CAR-T products has enabled treatment of over 34,000 patients to date. Since then, four additional CAR-T therapies have gained FDA approval [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>–<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. Complete responses (CR) in R/R B-cell lymphoblastic leukemia (B-ALL) have reached 71–81% in multicenter trials [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>, <a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>] and overall response rates (ORRs) of 73–98% have been reported in R/R multiple myeloma (MM) [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>–<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. Consequently, CAR-T therapy has become a cornerstone in treating hematologic malignancies, with indications expanding to earlier lines of therapy [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>, <a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>, <a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>].</p>
<p id="Par29">Nonetheless, long-term relapses remain common, and treatment-related toxicities are a major concern. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are the most frequent adverse events. Although their pathophysiology is not fully understood, current evidence suggests that cytokines secreted by T-cells activate myeloid cells, triggering further cytokine release and establishing a positive feedback loop known as cytokine storm [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>–<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>].</p>
<p id="Par30">Factors such as tumor burden, CAR-T design, and cell dose have been linked to CRS and ICANS [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. While higher CAR-T doses often correlate with more severe toxicities, a consistent dose–response relationship is not always observed [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. Rotte et al. proposed an optimal CAR-T dose that maximizes efficacy without increasing toxicity, suggesting that beyond this point, dose escalation adds risk without clinical benefit [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Current autologous CAR-T manufacturing quantifies dosage based solely on CAR-pos T-cells, overlooking the CAR-neg fraction. This results in substantial variability in total infused T-cell numbers across and within studies, complicating the establishment of a standardized optimal dose [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>, <a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>].</p>
<p id="Par31">To address these issues, our study aimed to improve CAR-T safety by analyzing our academic second-generation anti-BCMA CAR (CARTemis-1). We conducted immunophenotypic, functional, and transcriptomic profiling of both CAR-pos and CAR-neg cells to evaluate the impact of CAR-neg populations on the safety and efficacy of CAR-T therapy.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">CAR-T cell preparation</h3>
<p id="Par32">Human CD3 + cells were isolated, activated with CD3/CD28 Dynabeads (Gibco, 11131D) and transduced with an anti-BCMA CAR-T lentiviral vector co-expressing EGFRt as a safety/detection marker (CARTemis-1). Transduced cells were expanded with 50 IU/mL IL-2 (Miltenyi Biotec, 130-097-743) or 10 ng/mL IL-7 and IL-15 (Miltenyi Biotec, 130-095-367, 130–095-765) in RPMI (Gibco, 61870036) with 1% Pennicillin/Streptomycin (Gibco, 15140-122) and 10% fetal bovine serum (Gibco, 10270-106). Media was exchanged on alternate days and cytokines were added for 21 days.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Data from Tisagenlecleucel infusion products and toxicity.</h3>
<p id="Par33">Data from 31 Tisagenlecleucel products generated for patients with B-ALL or lymphoma were obtained after written informed consent. Percentage of CAR-pos cells, total cells/mL, volume and cell viability of the infused product were obtained from the Certificate of Analysis (CoA). CAR-pos/CAR-neg ratio was calculated by dividing the number of CAR-pos cells by the number of CAR-neg cells present in each product and correlated with CRS and ICANS data.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Flow cytometry</h3>
<p id="Par34">Cells were stained according to the antibodies and reagents described in Supplementary Table 1. CAR transduction was monitored by anti-EGFR staining (Biolegend, 352906) and immunophenotype characterization was performed according to Supplementary Table 1. Cell viability was analyzed by 7AAD- staining (BD Bioscience: 559925). Stained samples were acquired using a BD FACS Canto II and analyzed using FlowJo™ v10.7 Software (BD Life Sciences) and Infinicyt 2.0 (Cytognos) software.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Enhancers of the transduction assay</h3>
<p id="Par35">Different transduction enhancers were used, and transduction efficiency and cell proliferation were analyzed for 13 days of in vitro culture (n = 6). Polybrene 5 ug/mL (Santa Cruz Biotechnology, SC-134220), LentiBoost 0.1, 0.5, and 1 mg/mL (SIRION Biotech: SB-P-LV-101–01) and Vectofusin-1 10, 40, and 80 ug/mL (Miltenyi Biotec, 130–111-163) were added prior lentivirus and spinoculation following manufacturer’s instructions. Cell numbers and percentage of live CAR + cells were monitored for 13 days. Correlation between transduction and cell proliferation was assessed using Spearman’s Rho correlation.</p></section><section id="Sec7"><h3 class="pmc_sec_title">In vitro studies with CAR-pos and CAR-neg cells</h3>
<p id="Par36">CAR-pos and CAR-neg were purified by FACS from CARTemis-1 final product (n = 3). Total CARTemis-1 product was also sorted by CD3 + as control (non-purified product). Gating strategy is depicted in Supplementary Fig. 5. Cytotoxic activity from both purified populations and mixed CAR-pos/CAR-neg populations (n = 3) was analyzed in a bioluminescence-based assay using firefly luciferase (ffluc)-transduced target-cells at 5:1 effector-to-target-cell (E: T) ratio. IL-6, IFN-γ and GM-CSF secretion were measured by enzyme-linked immunosorbent assay (ELISA) (Biolegend) (n = 3) in supernatants obtained after a 24-h co-culture of T-cells (effector, E) with autologous PBMCs and target cells (E: PBMCs: target ratio of 5:5:1, respectively).</p></section><section id="Sec8"><h3 class="pmc_sec_title">Transcriptomic analysis</h3>
<p id="Par37">RNA from CAR-pos and CAR-neg FACS cells from three independent donors (n = 3) was isolated using RNeasy Mini Kit (Qiagen, 741049). cDNA library construction and Illumina sequencing were performed by NovoGene (Cambridge). The DEGs between the two samples were identified if they had a log2 (fold change) &lt;  − 0.5 or &gt; 0.5 and q (adjusted p value) &lt; 0.05. Gene ontology and KEGG pathway analyses were performed to analyze the gene enrichment of the DEGs, and those with corrected p &lt; 0,05 were considered as significantly enriched Gene ontology terms and pathways respectively.</p></section><section id="Sec9"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par38">Statistical analyses were performed using Prism software v6.07 (GraphPad, San Diego, California). Unpaired and paired t-tests were used to analyze data from in vitro experiments. P values &lt; 0.05 were considered statistically significant. The measurements per group were described by mean and standard error of the mean (SEM). When the qq plots showed no normally distributed data and due to the small sample size, non-parametric Mann–Whitney U tests were used as significance test for comparing the measurements between groups.</p></section></section><section id="Sec10"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec11"><h3 class="pmc_sec_title">CAR-neg population expands to a greater extent as compared to CAR-pos T-cells along ex vivo cell culture</h3>
<p id="Par39">CARTemis-1 is an academic anti-BCMA CAR-T containing 4-1BB costimulatory domain and the truncated form of the epidermal growth factor receptor (EGFRt) [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>] (Supplementary Fig. 1). The percentage of CAR-pos T-cells was significantly reduced throughout the ex vivo expansion both in CD4 and CD8 compartments and with both IL-2 and IL-7/IL-15 (n = 9) (e.g. CD4 + CAR-pos cells on day 8 was 37.83% vs 15.49% on day 15 with IL-7/IL-15, p &lt; 0.0001) (Fig. <a href="#Fig1" class="usa-link">1</a>A). Cell count of both populations confirms that CAR-neg cells expand significantly more rapidly with both cytokine cocktails (e.g. cell count of CD4 + CAR-pos cells on day 15 was 2.08 e<sup>6</sup> vs 3.45e<sup>6</sup> CD4 + CAR-neg cells with IL-7/IL-15, p = 0.001) (Fig. <a href="#Fig1" class="usa-link">1</a>B). Cell viability was monitored along the manufacturing and no significant differences were observed (Supplementary Fig. 2).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366063_12967_2025_6899_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f416/12366063/f53498e9f878/12967_2025_6899_Fig1_HTML.jpg" loading="lazy" id="MO1" height="991" width="779" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Transduction efficiency and in vitro expansion of CAR-pos and CAR-neg cells during the manufacturing procedure.<strong> A</strong> Percentage of CAR-pos T-cells at different time-points along the in vitro cell culture in CD4 + and CD8 + compartments and with IL-2 or IL-7/IL-15 (n = 9). <strong>B</strong> In vitro cell counts of CAR-pos or CAR-neg T-cells in CD4 + and CD8 + compartments and with IL-2 <em>(left)</em> or IL-7/IL-15 <em>(right)</em> during the 21 days of expansion (n = 9). <strong>C </strong>Transduction efficiency <em>(left)</em> and fold expansion in vitro<em> (right)</em> of CARTemis-1 cells exposed to different doses of lentiviral transduction enhancers (Polybrene, LentiBoost or Vectofusin-1) at different time-points along the manufacturing procedure (n = 6). <strong>D</strong> Spearman correlation between %CAR-pos T-cells and fold expansion in vitro (n = 6 independent healthy donors and 114 observations). Depicted are mean plus standard error of the mean (SEM) or individual values from 6 to 9 independent experiments. P-values between indicated groups were calculated using Student’s t-tests. Correlation was calculated using non-parametric Spearman’s rank correlation coefficient. *p &lt; 0.05, **p &lt; 0.01, **p &lt; 0.001, ***p &lt; 0.0001</p></figcaption></figure><p id="Par40">This was confirmed during CARTemis-1 production on the CliniMACS Prodigy under GMP standards. Percentage of CAR-pos cells significantly decreased, and this correlated with a greater expansion of CAR-neg cells (Supplementary Fig. 3).</p>
<p id="Par41">Lentiviral enhancers were tested to improve T-cell transduction and to assess their correlation with cell expansion (n = 6). Polybrene and LentiBoost significantly enhance lentiviral transduction compared to lentivirus alone in a dose-dependent manner (e.g. transduction with LentiBoost 1 mg/mL was 53.78% vs 36.32% with lentivirus alone, p = 0.0003) (Fig. <a href="#Fig1" class="usa-link">1</a>C). However, Vectofusin-1 significantly reduced lentiviral transduction (e.g. transduction percentage with Vectofusin-1 at 80 ug/mL was 20.50% vs 36.32% with lentivirus alone, p = 0.002) (Fig. <a href="#Fig1" class="usa-link">1</a>C). Confirming our previous results, we observed a significant inverse correlation between transduction and cell expansion during ex vivo cell culture (e.g. Spearman’s rho = -0.8594, p &lt; 0.0001) (Fig. <a href="#Fig1" class="usa-link">1</a>D). Therefore, as the proportion of CAR-pos cells increases in the culture, the overall fold expansion decreases due to their intrinsically lower proliferative capacity compared to CAR-neg cells.</p>
<p id="Par42">In conclusion, during CAR-T production, CAR-neg T-cells expand to a greater extent which translates into the dilution of CAR-pos T-cells and the reduction of the percentage of CAR-pos in the final product. These data suggest that expansion time is another variable to consider in the production process, validating in each case the optimal expansion time for each CAR product.</p></section><section id="Sec12"><h3 class="pmc_sec_title">CAR-pos T-cells show significantly increased levels of activation and exhaustion markers</h3>
<p id="Par43">Immunophenotypic characterization was performed by flow cytometry throughout the manufacturing procedure ex vivo. T-cell subpopulations were analyzed according to the following parameters: naïve (CCR7 + /CD45RA + /CD45RO-), central memory (CM) (CCR7 + /CD45RA-/CD45RO +), effector memory (EM) (CCR7-/CD45RA-/CD45RO +) and effector (EMRA) (CCR7-/CD45RA + /CD45RO-) (n = 5). No significant differences were observed between CAR-pos and CAR-neg cells in T-cell subpopulations at day 10 post-expansion with either IL-2 or IL-7/IL-15 (Fig. <a href="#Fig2" class="usa-link">2</a>). Similarly, no differences were observed at different time points post-activation (Supplementary Fig. 4).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366063_12967_2025_6899_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f416/12366063/0ff02d92d683/12967_2025_6899_Fig2_HTML.jpg" loading="lazy" id="MO2" height="526" width="783" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Memory subpopulation distribution of CAR-pos and CAR-neg cells during the manufacturing procedure. T-cell memory subpopulations distribution of CD4 and CD8 CAR-pos and CAR-neg T-cells at day 10 post-activation and expanded with IL-2 or IL-7/IL-15 (n = 5). Depicted are mean plus standard error of the mean (SEM) or individual values from 5 independent experiments. P-values between indicated groups were calculated using Student’s t-tests. *p &lt; 0.05, **p &lt; 0.01</p></figcaption></figure><p id="Par44">T-cell activation and exhaustion markers were also assessed by flow cytometry throughout the manufacturing procedure (n = 5). The percentage of CD25 + CD69 + was significantly increased in CAR-pos T-cells both with IL-2 or IL-7/IL-15 in the CD4 compartment (e.g. percentage of CD25 + CD69 + in CD4 CAR-pos was 15.88% vs 10.14% CAR-neg at day 21 with IL-2, p = 0.0083) (Fig. <a href="#Fig3" class="usa-link">3</a>A). Similarly, CD8 + CAR-pos T-cells showed significantly upregulated CD25 + CD69 + markers upon expansion with either IL-2 or IL-7/IL-15 (e.g. percentage of CD25 + CD69 + in CD8 CAR-pos was 10.51% vs 4.05% in CAR-neg at day 21, p = 0.0213) (Fig. <a href="#Fig3" class="usa-link">3</a>B). Co-inhibitory markers PD-1 and LAG-3 were significantly upregulated in CAR-pos at late time points post-activation with IL-2 or IL-7/IL-15 (e.g. percentage of PD-1 + /LAG-3 + in CD4 CAR-pos was 3.86% vs 2.01% in CAR-neg at day 21 with IL-2, p = 0.0082) (Fig. <a href="#Fig3" class="usa-link">3</a>). Of note, levels of PD-1 + /LAG-3 + were under 10% in both populations CAR-pos and CAR-neg.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366063_12967_2025_6899_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f416/12366063/b74d45023b27/12967_2025_6899_Fig3_HTML.jpg" loading="lazy" id="MO3" height="378" width="783" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Immunophenotypic characterization of CAR-pos and CAR-neg during manufacturing procedure. Activation (CD25 + CD69 +) (n = 5) and exhaustion (PD-1 + LAG-3 +) markers (n = 5) in CAR-pos and CAR-neg T-cells from CD4 (<strong>A</strong>) and CD8 (<strong>B</strong>) compartments expanded with IL-2 <em>(top)</em> or IL-7/IL-15 <em>(bottom).</em> Depicted are mean plus standard error of the mean (SEM) or individual values from 5 independent experiments. P-values between indicated groups were calculated using Student’s t-tests. *p &lt; 0.05, **p &lt; 0.01</p></figcaption></figure><p id="Par45">In conclusion, no differences were observed between CAR-pos and CAR-neg T-cells in the distribution of T-cell subpopulations (Naïve, CM, EM, EMRA) at any time-point through the manufacturing procedure. However, increased levels of T-cell activation and T-cell exhaustion were noted in CAR-pos T-cells along the ex vivo expansion both with IL-2 and IL-7/IL-15.</p></section><section id="Sec13"><h3 class="pmc_sec_title">Cytotoxicity assays comparing purified CAR-pos, mixed CAR-pos/CAR-neg populations and purified CAR-neg populations</h3>
<p id="Par46">CAR-pos and CAR-neg cells from three independent healthy donors were purified by FACS sorting to assess their function. Purified CAR-pos, purified CAR-neg or non-purified product (mixed CAR-pos/CAR-neg populations) were compared using cytotoxicity assays. Besides, to analyze the possible impact of CAR-neg T-cells in the efficacy of the final CAR-T cell product, mixed samples with different CAR-pos/CAR-neg T-cell ratios were included in the study. Purity of final sorted populations is depicted in Fig. <a href="#Fig4" class="usa-link">4</a>A. CAR-pos cells showed significantly higher cytotoxicity against two different myeloma cell lines compared to non-purified products (e.g. OPM-2 lysis with CAR-pos cells was 54.65% vs 33.98% with non-purified products, p = 0.0011) (Fig. <a href="#Fig4" class="usa-link">4</a>B, <a href="#Fig4" class="usa-link">4</a>C). Importantly, co-cultures used equal total T-cell numbers, highlighting that purified CAR-pos cells are more effective than non-purified products. No significant cytotoxicity was observed against control cell line K562 (Fig. <a href="#Fig4" class="usa-link">4</a>B, <a href="#Fig4" class="usa-link">4</a>C). Purified CAR-neg cells alone did not show significant cytotoxicity against MM cell lines or controls (Fig. <a href="#Fig4" class="usa-link">4</a>B,<a href="#Fig4" class="usa-link">4</a>C ). As additional controls, we included untransduced T-cells from the same healthy donors, both non-activated and activated with anti-CD3/CD28 and IL-7/IL-15, mimicking the CAR-T cell manufacturing protocol. Neither population showed significant cytotoxicity against MM cell lines or non-specific targets (Fig. <a href="#Fig4" class="usa-link">4</a>B, <a href="#Fig4" class="usa-link">4</a>C ). However, significant increased anti-myeloma efficacy was observed against both myeloma cell lines for the same number of CAR-pos cells when CAR-neg cells were added (e.g. MM.1S lysis with 10%CAR-pos cells alone was 8.87% vs 43.48% with 10%CAR-pos plus 90% CAR-neg cells, p &lt; 0.0001) (Fig. <a href="#Fig4" class="usa-link">4</a>C). It should be noted that different total T-cell numbers were used in these co-cultures. At a fixed number of CAR-pos (10,000), adding CAR-neg (90,000) increased cytotoxicity compared to 10,000 CAR-pos cells alone. This effect was not observed against the control cell line K562 (e.g. K562 lysis with 10%CAR-pos cells was 2.59% vs 0.96% with 10%CAR-pos + 90%CAR-neg cells, p = 0.5239).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366063_12967_2025_6899_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f416/12366063/81beec6e801f/12967_2025_6899_Fig4_HTML.jpg" loading="lazy" id="MO4" height="632" width="784" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Cytotoxicity assays of FACS-sorted CAR-pos and CAR-neg, or non-purified product against multiple-myeloma cell lines.<strong> A</strong> Representative example of cytometric plots showing the %CAR-pos of the FACS-sorted samples of non-purified final product, CAR-pos and CAR-neg populations. <strong>B</strong> Time-course of bioluminescence-based cytotoxicity assay of the effector- (CAR-pos, CAR-neg, non-purified product (30%CAR-pos + 70%CAR-neg), 10%CAR-pos + 0% CAR-neg or 10%CAR-pos + 90%CAR-neg)-to-target (MM.1S, OPM-2 or K562) ratio of 5:1 (n = 3 biological replicates). <strong>C</strong> Specific lysis of effector-(CAR-pos, CAR-neg, non-purified product (30%CAR-pos + 70%CAR-neg), 10%CAR-pos + 0% CAR-neg or 10%CAR-pos + 90%CAR-neg)-to-target (MM.1S, OPM-2 or K562) ratio of 5:1 at 24 h post-coculture (n = 3 biological replicates). Depicted are mean plus standard error of the mean (SEM) from 3 independent experiments, each tested in triplicate as technical replicates. P-values between indicated groups were calculated using Student’s t-tests. *p &lt; 0.05, **p &lt; 0.01, **p &lt; 0.001, ***p &lt; 0.0001</p></figcaption></figure><p id="Par47">In conclusion, 100% CAR-pos purified product shows increased specific lysis of myeloma cells compared to non-purified product. However, at the same number of CAR-pos cells, adding CAR-neg cells increases the anti-myeloma efficacy against both MM.1S and OPM-2 without increasing the cytotoxicity against K562.</p></section><section id="Sec14"><h3 class="pmc_sec_title">Co-cultures of purified CAR-pos cells plus tumor cells and autologous PBMCs show reduced secretion of IL-6 as compared to non-purified products</h3>
<p id="Par48">To assess potential toxicity of purified CAR-pos, CAR-neg, and non-purified products, secretion of CRS-related cytokines was measured by ELISA. Figure  <a href="#Fig5" class="usa-link">5</a>A outlines the experimental design. CAR-pos and CAR-neg T-cells from three healthy donors (each tested in triplicate) were FACS-sorted on day 10 post-activation. Effectors (CAR-pos, CAR-neg, or non-purified), MM.1S target cells, and autologous CD3-depleted PBMCs were co-cultured. After 24 h, supernatants were collected for ELISA. As a control, 30,000 purified CAR-pos cells (matching the CAR-pos content in non-purified products) were tested without CAR-neg cells (Fig. <a href="#Fig5" class="usa-link">5</a>A). IL-6 levels were significantly higher with non-purified products (mixed CAR-pos/CAR-neg) compared to purified CAR-pos cells (p = 0.0002) (Fig. <a href="#Fig5" class="usa-link">5</a>B). At the same time, the non-purified product also displayed significantly higher levels of IL-6 as compared to equal number (30,000) CAR-pos cells alone (p &lt; 0.0001) (Fig. <a href="#Fig5" class="usa-link">5</a>B). Other CRS-related cytokines such as IFN-γ and GM-CSF were also quantified showing significantly higher levels in non-purified products compared to the same number of CAR-pos cells alone (Fig. <a href="#Fig5" class="usa-link">5</a>C, <a href="#Fig5" class="usa-link">5</a>D, p= 0.0094 and p = 0.0033, respectively).</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366063_12967_2025_6899_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f416/12366063/2e709d0aa018/12967_2025_6899_Fig5_HTML.jpg" loading="lazy" id="MO5" height="699" width="783" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Impact of CAR-neg population on cytokine secretion and clinical correlations in CAR-T Therapy. <strong>A</strong> Schematic representation of the workflow representing the purification of populations by FACS sorting using BD FACS Aria Fusion and the seeding of the 96-well plate with effector: PBMCs: target cells ratio of 5:5:1 by triplicate (effector: CAR-pos, CAR-neg, non-purified product or 30%CAR-pos only, target: MM.1S myeloma cell line). Finally, ELISA assays were performed for each cytokine using Biolegend kits following manufacturer’s instructions. <strong>B</strong> Normalized IL-6, <strong>C</strong> IFN-γ and <strong>D</strong> GM-CSF levels quantified at 24 h post-coculture of the different samples described (purified 100%CAR-pos, non-purified CARTemis-1 product, 30% CAR-pos cells only or purified 100%CAR-) with autologous CD3-depleted PBMCs and MM.1S cells (n = 3 biological replicates). Normalization was performed by calculating the ratio value/baseline of pg/mL secreted, making purified 100%CAR-pos condition the baseline. Depicted are mean plus SEM from 3 independent experiments, each tested in triplicate as technical replicates. <strong>E</strong> CAR-pos/CAR-neg ratio of the Tisagenlecleucel infusion products of 31 patients suffering from patients with CRS grades 0–1 versus 2–3 (<em>left)</em> or ICANS grades 0–1 versus grades 2–3. <strong>F</strong> Spearman correlation between CAR-pos/CAR-neg ratio and days that elapsed from infusion to the onset of CRS symptoms (n = 29 and 29 observations). P-values between indicated groups were calculated using Student’s t-tests. *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001, ****p &lt; 0.0001</p></figcaption></figure><p id="Par49">To assess whether a lower CAR-pos/CAR-neg ratio in infusion products correlates with increased toxicity, data from 31 Tisagenlecleucel products were analyzed using logistic regression against CRS and ICANS. Patient characteristics, including disease, age, sex, infused dose, and toxicity incidence, are shown in Table <a href="#Tab1" class="usa-link">1</a>. More detailed clinical data, including treatment-related variables and toxicity profiles relevant to the analysis, is shown in Table <a href="#Tab2" class="usa-link">2</a>. CAR-pos/CAR-neg ratio was compared between patients with severe toxicity (CRS or ICANS grades 2–3) and those with no toxicity or only mild symptoms (CRS or ICANS grades 0–1). No significant differences were observed considering CRS; however, those patients experiencing ICANS grades 2–3 tended to a reduced CAR-pos frequency (p = 0.08) (Fig. <a href="#Fig5" class="usa-link">5</a>E). To mitigate the potential biases introduced by toxicity treatments, corticosteroids and tocilizumab, we analyzed the time from CAR-T cell infusion to the onset of symptoms. We observed a significant correlation between an increased CAR-pos frequency in the infusion product and a delay in the onset of CRS (Spearman’s ρ = 0.3827, p = 0.04) (Fig. <a href="#Fig5" class="usa-link">5</a>F). ICANS onset correlation could not be assessed due to low case numbers.</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Characteristics of the patients included in the study</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Patients (n)</th>
<th align="left" colspan="1" rowspan="1">31</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">DLBCL</td>
<td align="left" colspan="1" rowspan="1">7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">FL</td>
<td align="left" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">B-ALL</td>
<td align="left" colspan="1" rowspan="1">23</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Previous lines of treatment (range)</td>
<td align="left" colspan="1" rowspan="1">2 (1–5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Median age (range)</td>
<td align="left" colspan="1" rowspan="1">29.3 (2–73)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sex (%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Female</td>
<td align="left" colspan="1" rowspan="1">17 (54.84)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Male</td>
<td align="left" colspan="1" rowspan="1">14 (45.16)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Median weight (range)</td>
<td align="left" colspan="1" rowspan="1">57.25 (12.7–96)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Transduction efficiency (range)</td>
<td align="left" colspan="1" rowspan="1">15 (3.3–27.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Infused dose (× 10<sup>6</sup>) (range)</td>
<td align="left" colspan="1" rowspan="1">150 (26.3–420)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CRS grade (%)</td>
<td align="left" colspan="1" rowspan="1">29 (93.5)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  0</td>
<td align="left" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  1</td>
<td align="left" colspan="1" rowspan="1">15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  2</td>
<td align="left" colspan="1" rowspan="1">12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  3</td>
<td align="left" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ICANS grade (%)</td>
<td align="left" colspan="1" rowspan="1">7 (22.6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  0</td>
<td align="left" colspan="1" rowspan="1">24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  1</td>
<td align="left" colspan="1" rowspan="1">4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  2</td>
<td align="left" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  3</td>
<td align="left" colspan="1" rowspan="1">2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Treatment for toxicity (%)</td>
<td align="left" colspan="1" rowspan="1">14 (45.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Corticosteroids</td>
<td align="left" colspan="1" rowspan="1">1 (3.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Tocilizumab</td>
<td align="left" colspan="1" rowspan="1">13 (41.9)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p34"><p><em>DLBCL</em> diffuse large B-cell lymphoma, <em>FL</em> follicular lymphoma, <em>B-ALL</em> B-cell acute lymphoblastic leukemia, <em>CRS</em> cytokine release syndrome, <em>ICANS</em> immune effector cell-associated neurotoxicity syndrome</p></div></div></section><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Clinical characteristics of the patient cohort (n = 31)</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Patients (n)</th>
<th align="left" colspan="1" rowspan="1">31</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Time since diagnose, years (range)</td>
<td align="left" colspan="1" rowspan="1">3 (1–19)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lenght of hospital stay, days (range)</td>
<td align="left" colspan="1" rowspan="1">20 (14–44)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Time to CRS, days (range)</td>
<td align="left" colspan="1" rowspan="1">1 (0–8)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CRS length, days (range)</td>
<td align="left" colspan="1" rowspan="1">5 (1–11)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Time to ICANS, days (range)</td>
<td align="left" colspan="1" rowspan="1">6 (4–7)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ICANS length, days (range)</td>
<td align="left" colspan="1" rowspan="1">4 (1–8)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ICU admission (%)</td>
<td align="left" colspan="1" rowspan="1">5 (16.13)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">High tuomor burden (%)</td>
<td align="left" colspan="1" rowspan="1">15 (48.39)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Previous transplant (%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Allo</td>
<td align="left" colspan="1" rowspan="1">16 (51.61)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Auto</td>
<td align="left" colspan="1" rowspan="1">2 (6.45)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">13(41.93)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Previous bispecific antibodies (%)</td>
<td align="left" colspan="1" rowspan="1">9 (29.03)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p36"><p>Data are presented as median (range) or n (%), as appropriate. “Time since diagnosis” refers to the interval between initial diagnosis and CAR-T cell infusion. “Length of hospital stay” refers to the total number of days since hospital admission to hospital discharge related to the CAR-T cell infusion. “CRS” and “ICANS” represent cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, respectively. “Time to CRS/ICANS” refers to the number of days from infusion to onset, while “CRS/ICANS length” indicates the duration of each toxicity episode. ICU admission refers to any patient requiring intensive care support post-infusion. High tumor burden was defined as &gt; 5% of blasts in bone marrow for B-ALL and active disease for lymphoma patients. “Previous transplant” includes allogeneic (Allo) and autologous (Auto) hematopoietic stem cell transplantation. Prior treatment with bispecific antibodies before CAR-T infusion is also reported</p></div></div></section><p id="Par50">In conclusion, non-purified CAR-T products showed higher secretion of CRS-related cytokines in vitro, and clinical data suggested that lower CAR-pos frequency in infusion products may be associated with earlier CRS onset and a trend toward higher ICANS severity.</p></section><section id="Sec15"><h3 class="pmc_sec_title">CAR-pos and CAR-neg cells show differential transcriptomic profile</h3>
<p id="Par51">CAR-pos and CAR-neg cells from three independent healthy donors were sorted from the final product and total RNA was sequenced. Principal Component Analysis (PCA) showed that samples clustered primarily by donor rather than by CAR expression (Supplementary Fig. 7).</p>
<p id="Par52">Differential gene expression (DEG) and clustering was compared between CAR-pos and CAR-neg populations. The Venn diagram indicated that 12,740 genes were commonly expressed in both populations, while 467 genes were unique to CAR-pos, and 406 genes were unique to CAR-neg cells (Fig. <a href="#Fig6" class="usa-link">6</a>A). Performing DEG analysis, we found 70 upregulated and 271 downregulated genes in CAR-pos compared to the CAR-neg. As expected, EGFR was the most significantly upregulated gene in CAR-pos T-cells (fold change = 5.43, p &lt; 0.0001), reflecting its inclusion in the CAR construct (Supplementary Fig. 8). Excluding EGFR, genes upregulated in the CAR-neg population include granzyme B (GRZMB) (fold change = -1.50, p &lt; 0.0001), perforin-1 (PRF1A) (fold change = -1.03, p &lt; 0.0001), CD8A (fold change = -1.01, p &lt; 0.0001), and killer cell lectin receptor D1 (KLRD1) (fold change = -1.56, p &lt; 0.0001) (Fig. <a href="#Fig6" class="usa-link">6</a>B). Upregulated genes in CAR-pos cells include ribosomal protein pseudogene (RPL7AP6) (fold change = 1.23, p &lt; 0.0001), membrane spanning 4-domains A1 (MS4A1) (fold change = 6.88, p &lt; 0.0001), immunoglobulin heavy constant gamma 3 (IGHG3) (fold change = 6.57, p &lt; 0.0001), or cholinergic receptor nicotinic alpha 6 subunit (CHRNA6) (fold change = 1.67, p &lt; 0.0001) (Fig. <a href="#Fig6" class="usa-link">6</a>B). All significant differentially expressed genes, fold expansion and p-value are included in Supplementary Table 2.</p>
<figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366063_12967_2025_6899_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f416/12366063/bcbcc8bf153e/12967_2025_6899_Fig6_HTML.jpg" loading="lazy" id="MO6" height="810" width="784" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Transcriptomic analysis of FACS-sorted CAR-pos and CAR-neg cells. <strong>A</strong> Venn diagram of CAR-pos and CAR-neg cells gene expression. <strong>B</strong> Volcano plot of the gene expression of CAR-pos versus CAR-neg cells excluding EGFR gene expression. <strong>C</strong> Dot plot gene enrichment analysis of the downregulated pathways in CAR-pos cells according to Kyoto Encyclopedia Genes and Genomes database. <strong>D</strong> Dot plot gene enrichment analysis of the upregulated pathways in CAR-pos cells according to Kyoto Encyclopedia Genes and Genomes database. Bulk RNA-seq was performed from sorted CAR-pos and CAR-neg cells from 3 independent healthy donors (biological replicates)</p></figcaption></figure><p id="Par53">Finally, gene set enrichment analysis (GSEA) was performed to analyze the biological and functional implications of the differentially expressed genes. We performed gene enrichment analysis according to Kyoto Encyclopedia of Genes and Genomes (KEGG) database. CAR-neg cells showed upregulation of the natural killer and cell mediated cytotoxicity pathway (KEGGID: hsa04650) (enrichment = 7.57, p &lt; 0.0001), viral protein interaction with cytokine and cytokine receptor pathway (KEGGID: hsa04061) (enrichment = 9.72, p &lt; 0.0001), chemokine signaling pathway (KEGGID: hsa04062) (enrichment = 7.4, p &lt; 0.0001), antigen processing and presentation (KEGGID: hsa04612, p &lt; 0.0001), or graft-versus-host disease (GvHD) (KEGGID: hsa05332) (enrichment = 11.43, p &lt; 0.0001) (Fig. <a href="#Fig6" class="usa-link">6</a>C). On the other side, CAR-pos T-cells showed upregulation of PD-L1 expression and PD-1 checkpoint (KEGGID: hsa05235) (enrichment = 12.19, p &lt; 0.0001), Th17 cell differentiation (KEGGID: hsa0465) (enrichment = 9.59, p &lt; 0.0001), cytokine-cytokine receptor interaction (KEGGID: hsa04060) (enrichment = 5.45, p &lt; 0.0001), or Th1 and Th2 cell differentiation (KEGGID: hsa04658) (enrichment = 9.05, p &lt; 0.0001) (Fig. <a href="#Fig6" class="usa-link">6</a>D). Data from the KEGG analysis of downregulated and upregulated pathways in CAR-pos cells are depicted in Supplementary Table 3 and Supplementary Table 4, respectively.</p>
<p id="Par54">In summary, RNA-sequencing of CAR-pos and CAR-neg cells showed a significantly different gene expression pattern (Fig. <a href="#Fig6" class="usa-link">6</a>).</p></section></section><section id="Sec16"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par55">Despite the remarkable efficacy of CAR-T therapy, a significant proportion of patients fail to respond or eventually relapse. In addition, significant side-effects have been reported [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. Several studies highlight the prognostic value of product characteristics. In this context, significant inter-trial variability, particularly in transduction rates, has been reported in the infusion product, with mean efficiencies ranging from 20% [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>] to 70% [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]. Even within the same trial, transduction efficiency varies widely among patients [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>, <a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. In our study, infusion products showed a mean transduction efficiency of 15%, ranging from 3.3 to 27.5%. Moreover, some commercial CAR-T products do not report CAR-pos percentage. Since CAR-T dosing is based on viable CAR-pos cells, this high variability affects the total T-cell dose infused. Additionally, characterization of CAR-neg T-cells is scarce. Such variability complicates the identification of predictive biomarkers. Therefore, we conducted a phenotypic and functional characterization of CAR-pos and CAR-neg T-cells from our academic anti-BCMA CAR-T product throughout the manufacturing process to better understand their respective contributions to efficacy and toxicity.</p>
<p id="Par56">A significant decrease in the percentage of CAR-pos cells was noted in vitro throughout culture at both preclinical and clinical scales, while CAR-neg cell counts significantly increased. This suggests that CAR-neg cells proliferate more than CAR-pos cells, regardless of cytokines used (IL-2 or IL-7/IL-15) diluting CAR-pos population in the final product. Besides, using different lentiviral enhancers we found a strong inverse correlation between transduction efficiency and the total T-cell expansion ex vivo, suggesting that transduced CAR-pos cells may proliferate less efficiently than CAR-neg cells. Besides, while Polybrene and LentiBoost enhanced transduction in a dose-dependent manner, Vectofusin-1 unexpectedly reduced CAR expression in our cultures. This is consistent with previous studies reporting that the effect of Vectofusin-1 depends on the vector pseudotype. Specifically, while it enhances transduction of receptor-targeted lentiviruses, it can impair that of VSV-G pseudotyped vectors, likely due to differences in viral entry routes, plasma membrane fusion (pH-independent) versus endosomal fusion under low pH [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>, <a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Therefore, we confirmed that increased CAR-T cell transduction results in lower T-cell counts ex vivo, which might be explained by the reduced proliferation capacity of CAR-pos T-cells compared to CAR-neg cells. Consequently, after a certain point of expansion, the proportion of CAR-pos cells diminishes relative to the total cell population. Thus, defining an optimal expansion window is essential to favor CAR-pos growth and limit CAR-neg overgrowth.</p>
<p id="Par57">Additionally, immunophenotyping revealed higher activation and exhaustion marker expression in CAR-pos cells. Reduced proliferation is a hallmark of T-cell exhaustion [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>], and co-inhibitory receptors like PD-1, LAG-3, and TIM-3 are known to limit T-cell expansion [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>–<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]<em>.</em> Antigen-independent CAR signaling also contributes to tonic activation and exhaustion [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>, <a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]. Previous studies described that CAR-T cells with high CAR expression (CAR<sup>High</sup>) show increased exhaustion levels, tonic signaling, and reduced expansion in vitro [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. In this context, strong promoters like EF1α may drive excessive CAR expression, impairing proliferation. Notably, although PD-1 + /LAG-3 + levels were increased in CAR-pos cells at later stages of the culture, particularly under IL-2 and in CD8 + compartment, expression levels remained below 10%.</p>
<p id="Par58">Regarding in vitro efficacy, purified CAR-pos product was significantly more effective against myeloma cell lines than non-purified CAR T-cells at equal number of total T-cells, due to higher CAR-pos cell proportion (100% vs. ~ 30%). However, unexpectedly, products with 10% (10,000) CAR-pos cells and 90% (90,000) CAR-neg cells exhibited significantly enhanced cytotoxicity compared to the purified product containing 10,000 CAR-pos T-cells only, suggesting a bystander effect. This was absent upon stimulation with the control cell line K562 (BCMA-negative). Kaminski et al., described expansion of CD8 + CAR-neg cells in non-human primates (NHP) in parallel to CAR-pos cells. CAR-neg cells were sorted at peak expansion in NHP, and single cell RNA sequencing (scRNA-seq) revealed increased expression of canonical NK genes and CD8 + effector markers related to TCR-independent cytotoxic alternative pathways. IL-2 and IL-15 gamma cytokines were identified as the major drivers of this differentiation of CD8 + bystander activated phenotype. Besides, CD8 + CAR-neg bystander T-cells showed in vitro anti-tumoral activity against leukemic cells after IL-15 stimulation [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. A previous study also reported a bystander activation in the context of CAR T-cell therapy where a substantial number of CAR-neg T-cells in the tumor microenvironment showed activation markers such as Ki67, IFN-γ or granzyme-B 5 days post-treatment [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. In this regard, CAR-neg cells from our IL-7 and IL-15 expanded anti-BCMA CAR T-cell product exhibited a bystander T-cell activation in the presence of CAR-pos cells and myeloma cells. This activation significantly enhanced the anti-tumoral effect of CAR-pos T-cells alone.</p>
<p id="Par59">Concerning cytokine release, non-purified product (~ 30% CAR-pos) showed a significant increase of IL-6 compared to purified 100% CAR-pos product. This aligns with previous studies identifying non-CAR immune cells in the tumor microenvironment as the main source of IL-6 [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. Secretion of IFN-γ and GM-CSF also tended to be higher in non-purified products. Kaminski et al., also described an increase of effector and cytolytic cytokines (IFN-γ, IL-2) secreted by CD8 + CAR-neg cells [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. Moreover, patients receiving products with higher CAR-pos/CAR-neg ratio experienced lower grades of ICANS and showed a delay in the onset of CRS. Lee et al. reported that mice infused with the lowest-purity CAR-T product showed the greatest in vivo CAR-T expansion and were the only ones to exhibit significant weight loss [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. In Deng et al., a significant lower percentage of CAR-pos cells was observed in the infusion products of patients experiencing ICANS grades 3–4 compared to patients suffering grades 0–2 ICANS.</p>
<p id="Par60">RNA-sequencing revealed distinct transcriptomic profiles between CAR-pos and CAR-neg T cells. Key upregulated genes in CAR-neg cells included GRZB, PRF1A, CD8A, KLRD1, KLRC1, CCL5 (Supplementary Table 2). Flow cytometry of GMP-manufactured CARTemis-1 products showed an increased proportion of CD4 + cells in CAR-pos cells, consistent with RNA-seq data where CD8A/CD8B were upregulated in CAR-neg and CD4 in CAR-pos cells (Supplementary Fig. 6). This matches previous studies reporting an increased expansion of CD8 cells within the CAR-neg fraction in vivo and in the tumor microenvironment [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>, <a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. Kaminski et al., identified a CD8 + CAR-neg population within an anti-CD20 CAR T-cell product expressing NK cell markers and cytolytic cytokines such as granzyme B and perforin-1. In Louie et al., this CD8 + CAR-neg population was also identified post-infusion in B-ALL and lymphoma patients [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. The phenotypic profile described in both studies (CD8A + , CD160 + , KLRK1 + (NKG2D +), KLRD1 + (CD94 +), CCL5 +) closely resembles our CAR-neg T-cells. Notably, NK cytotoxicity pathway (hsa04650) was the most upregulated in CAR-neg cells, including genes such as GRZMB, PRF1A, KLRD1, KLRC1, and KLRK1. In this context, this population may be relevant for ongoing clinical trials that include IL-15 in the manufacturing process and that may incorporate this bystander CD8 + CAR-neg signature within the final product. Another upregulated pathway in CAR-neg T-cells is the GvHD pathway (has05332), with increased expression of genes like GZMB, PRF1, KLRD1, KLRC1, KIR2DS4, and KIR3DX1, potentially contributing to the bystander effect and amplifying the cytokine storm feedback loop.</p>
<p id="Par61">Conversely, CAR-pos T-cells showed upregulation of immune checkpoint-related pathways, notably the PD-L1/PD-1 pathway (hsa05235), consistent with higher PD-1 and LAG-3 expression observed by flow cytometry. Enrichment of Th17 (hsa04659) and Th1/Th2 (hsa04658) differentiation pathways also suggested modulation of helper T-cell responses, key for antitumor immunity. Th17 cells display potent antitumor effects and can enhance the persistence of adoptively transferred T-cells [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. Overall, CAR-pos and CAR-neg T-cells displayed distinct transcriptional profiles, with CAR-neg cells showing features resembling the bystander CD8 + activation signature.</p>
<p id="Par62">Through this study, we provide new insights into the largely understudied CAR-neg population found in CAR-T cell products and infused into patients. These findings highlight the need for further investigation into its role and potential impact on therapeutic outcomes. In the clinical setting, limited access to CAR-pos and CAR-neg frequencies in commercial products, as well as the small patient cohort, limited deeper correlative analyses. Future studies should validate these findings in other CAR-T cell products and in larger patient cohorts to strengthen clinical relevance and reproducibility. This approach aligns with the growing emphasis on precision medicine and personalized therapeutics in oncology and could offer a promising avenue for optimizing CAR-T therapy and enhancing patient outcomes.</p></section><section id="Sec17"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par63">In conclusion, the role of CAR-neg cells in CAR-T-cell infusion products remains poorly understood, with limited data on their impact on safety and efficacy. Here, we characterized this population during the manufacturing of our academic anti-BCMA CAR-T product, CARTemis-1 (26). CAR-neg T-cells expand significantly more than CAR-pos cells, reducing the proportion of CAR-pos cells in the final product. This underscores the need to define an optimal expansion period that favors CAR-pos proliferation while limiting CAR-neg overgrowth. Although CAR-neg cells lack specific cytotoxic activity, a bystander effect is observed in the presence of CAR-pos cells. Notably, purified CAR-pos cells secrete significantly less IL-6, a key cytokine implicated in CRS and ICANS. We suggest that selecting CAR-pos cells prior to infusion could reduce total T-cell numbers, limit interpatient variability, and potentially lower the incidence and severity of adverse events.</p></section><section id="Sec18"><h2 class="pmc_sec_title">Supplementary Information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM1_ESM.docx</a><sup> (811.8KB, docx) </sup><p>Supplementary Material 1. Supplementary Figures.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM2_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM2_ESM.pdf</a><sup> (121.3KB, pdf) </sup><p>Supplementary Material 2. Supplementary Table 1.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM3_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM3_ESM.pdf</a><sup> (360.9KB, pdf) </sup><p>Supplementary Material 3. Supplementary Table 2.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM4"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM4_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM4_ESM.pdf</a><sup> (98.4KB, pdf) </sup><p>Supplementary Material 4. Supplementary Table 3.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM5"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM5_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM5_ESM.pdf</a><sup> (100.3KB, pdf) </sup><p>Supplementary Material 5. Supplementary Table 4</p>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>This work has been supported by the Instituto de Salud Carlos III (ISCIII), Project RD21/0017/0021, Project ICI20/0118, and Project PI20/01792 by the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS)-TERAV funded by European Union-NextGenerationEU. “Plan de Recuperación Transformación y Resiliencia”; and by the Ministerio de Ciencia e Innovación Project EQC2019-006475-P.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>CAR-T</dt>
<dd><p id="Par5">Chimeric Antigen Receptor</p></dd>
<dt>R/R</dt>
<dd><p id="Par6">Relapsed/refractory</p></dd>
<dt>CR</dt>
<dd><p id="Par7">Complete response</p></dd>
<dt>B-ALL</dt>
<dd><p id="Par8">B-cell acute lymphoblastic leukemia</p></dd>
<dt>ORRs</dt>
<dd><p id="Par9">Overal response rates</p></dd>
<dt>MM</dt>
<dd><p id="Par10">Multiple myeloma</p></dd>
<dt>CRS</dt>
<dd><p id="Par11">Cytokine release syndrome</p></dd>
<dt>ICANS</dt>
<dd><p id="Par12">Immune effector cell-associated neurotoxicity syndrome</p></dd>
<dt>CoA</dt>
<dd><p id="Par13">Certificate of Analysis</p></dd>
<dt>CAR-pos</dt>
<dd><p id="Par14">CAR-positive</p></dd>
<dt>CAR-neg</dt>
<dd><p id="Par15">CAR-negative</p></dd>
<dt>FACS</dt>
<dd><p id="Par16">Fluorescence-activated cell sorting</p></dd>
<dt>SEM</dt>
<dd><p id="Par17">Standard error of the mean</p></dd>
<dt>EGFRt</dt>
<dd><p id="Par18">Truncated form of epidermal growth factor receptor</p></dd>
<dt>CM</dt>
<dd><p id="Par19">Central memory</p></dd>
<dt>EM</dt>
<dd><p id="Par20">Effector memory</p></dd>
<dt>EMRA</dt>
<dd><p id="Par21">Effector</p></dd>
<dt>PCA</dt>
<dd><p id="Par22">Principal Component Analysis</p></dd>
<dt>DEG</dt>
<dd><p id="Par23">Differential gene expression</p></dd>
<dt>GSEA</dt>
<dd><p id="Par24">Gene set enrichment analysis</p></dd>
<dt>KEGG</dt>
<dd><p id="Par25">Kyoto Enciclopedia of Genes and Genomes</p></dd>
<dt>scRNA-seq</dt>
<dd><p id="Par26">Single cell RNA sequencing</p></dd>
<dt>NHP</dt>
<dd><p id="Par27">Non-human primates</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>B.S.M designed and performed experiments, analyzed data, and wrote the manuscript. B.G.A, P.H.D, M.R.G, I.C.B, and M.L.C contributed to the in vitro characterization of CAR-pos and CAR-neg populations and data analysis. R.F.C, A.R.G and F.G.C contributed to the RNA-seq data analysis and interpretation. V.E.G, R.M.G and A.B contributed to patient data collection and analysis. J.A.P.S and E.G.G designed experiments and projects and critically reviewed the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This project was supported by the Instituto de Salud Carlos III (ISCIII) through the Clinical trial ICI20/00118 and the research project grant PI24/01700 (FIS), and by the Miguel Servet contract from the Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (CP23/00139) awarded to Dr. García-Guerrero. Additional funding was provided by the Junta de Andalucía through grant PI-0100-2024 and by the Red de Investigación Cooperativa Orientada en Salud en Terapias Avanzadas (RICORs-TERAV).</p></section><section id="notes3"><h2 class="pmc_sec_title">Availability of data and materials</h2>
<p>The data generated in this study is available upon request to the corresponding author.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par64">Peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats of healthy donors kindly donated by the Regional Centre for Blood Transfusions at Virgen del Rocío University Hospital, Sevilla (Spain) after written informed consent. Leukapheresis from healthy donors were obtained from the leukapheresis unit of the Virgen del Rocío University Hospital, Sevilla (Spain) after written informed consent.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par65">All authors consent for publication.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par66">J.A.P.S is an advisor or consultant for Novartis, Janssen, Roche, Jazz Pharmaceuticals, Amgen, and Gilead Sciences; reports research support from Novartis, Janssen, Pfizer, Roche, and Takeda; reports travel support from Roche, Gilead Sciences and Janssen; and reports patents, royalties, or other intellectual property from Entourage Bioscience on cannabinoid derivatives. E.G.G has been a consultant to Cellgene and GLS, and received travel grants and/or speaker fees from Cellgene, Amgen, Janssen. E.G.G is a co-inventor on a patent application on the use of BCMA-CAR T-cell therapy in combination with ATRA, “Combination treatment of BCMA CAR-T and ATRA in multiple myeloma” (WO2021/209498 A1), that has been filed by the University of Würzburg, Würzburg, Germany and licensed to T-CURX GmbH, Würzburg, Germany.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Jose Antonio Pérez-Simón, Email: josea.perez.simon.sspa@juntadeandalucia.es.</p>
<p>Estefanía García-Guerrero, Email: egarcia-ibis@us.es.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, Horwitz EM, Grupp SA, Maus MV, Locke FL, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30:338–41. 10.1038/s41591-023-02767-w.
</cite> [<a href="https://doi.org/10.1038/s41591-023-02767-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11688691/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38195751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Levine%20BL,%20Pasquini%20MC,%20Connolly%20JE,%20Porter%20DL,%20Gustafson%20MP,%20Boelens%20JJ,%20Horwitz%20EM,%20Grupp%20SA,%20Maus%20MV,%20Locke%20FL,%20et%20al.%20Unanswered%20questions%20following%20reports%20of%20secondary%20malignancies%20after%20CAR-T%20cell%20therapy.%20Nat%20Med.%202024;30:338%E2%80%9341.%2010.1038/s41591-023-02767-w." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71. 10.1038/s41571-023-00754-1.
</cite> [<a href="https://doi.org/10.1038/s41571-023-00754-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10100620/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37055515/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cappell%20KM,%20Kochenderfer%20JN.%20Long-term%20outcomes%20following%20CAR%20T%20cell%20therapy:%20what%20we%20know%20so%20far.%20Nat%20Rev%20Clin%20Oncol.%202023;20:359%E2%80%9371.%2010.1038/s41571-023-00754-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145–61.
</cite> [<a href="https://doi.org/10.1038/s41568-020-00323-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8353572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33483715/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Larson%20RC,%20Maus%20MV.%20Recent%20advances%20and%20discoveries%20in%20the%20mechanisms%20and%20functions%20of%20CAR%20T%20cells.%20Nat%20Rev%20Cancer.%202021;21:145%E2%80%9361." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. 2021. 10.1016/S0140-6736(21)01222-8</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)01222-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11613962/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34097852/" class="usa-link">PubMed</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Andr A, Baruchel A, Boyer M, De Moerloose B, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2022;41:1664–9. 10.1200/JCO.22.
</cite> [<a href="https://doi.org/10.1200/JCO.22.00642" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10022844/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36399695/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Laetsch%20TW,%20Maude%20SL,%20Rives%20S,%20Hiramatsu%20H,%20Bittencourt%20H,%20Bader%20P,%20Andr%20A,%20Baruchel%20A,%20Boyer%20M,%20De%20Moerloose%20B,%20et%20al.%20Three-year%20update%20of%20tisagenlecleucel%20in%20pediatric%20and%20young%20adult%20patients%20with%20relapsed/refractory%20acute%20lymphoblastic%20leukemia%20in%20the%20ELIANA%20trial.%20J%20Clin%20Oncol.%202022;41:1664%E2%80%939.%2010.1200/JCO.22." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Martin T, Saad ;, Usmani Z, Berdeja JG, Agha ; Mounzer, Cohen AD, Hari P, Avigan D, Deol A, Htut M, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. 2022. 1265–1274. </cite> [<a href="https://doi.org/10.1200/JCO.22.00842" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9937098/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35658469/" class="usa-link">PubMed</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29:2286–94. 10.1038/s41591-023-02496-0.
</cite> [<a href="https://doi.org/10.1038/s41591-023-02496-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10504071/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37592106/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lin%20Y,%20Raje%20NS,%20Berdeja%20JG,%20Siegel%20DS,%20Jagannath%20S,%20Madduri%20D,%20Liedtke%20M,%20Rosenblatt%20J,%20Maus%20MV,%20Massaro%20M,%20et%20al.%20Idecabtagene%20vicleucel%20for%20relapsed%20and%20refractory%20multiple%20myeloma:%20post%20hoc%2018-month%20follow-up%20of%20a%20phase%201%20trial.%20Nat%20Med.%202023;29:2286%E2%80%9394.%2010.1038/s41591-023-02496-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, Chen LJ, Hou J, Chen Z, Zhao WH, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17:1–13. 10.1186/S13045-024-01530-Z/FIGURES/4.
</cite> [<a href="https://doi.org/10.1186/s13045-024-01530-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11040812/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38659046/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20J,%20Wang%20BY,%20Yu%20SH,%20Chen%20SJ,%20Yang%20SS,%20Liu%20R,%20Chen%20LJ,%20Hou%20J,%20Chen%20Z,%20Zhao%20WH,%20et%20al.%20Long-term%20remission%20and%20survival%20in%20patients%20with%20relapsed%20or%20refractory%20multiple%20myeloma%20after%20treatment%20with%20LCAR-B38M%20CAR%20T%20cells:%205-year%20follow-up%20of%20the%20LEGEND-2%20trial.%20J%20Hematol%20Oncol.%202024;17:1%E2%80%9313.%2010.1186/S13045-024-01530-Z/FIGURES/4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, Fernández de Larrea C, Martínez-López J, Moreau P, Touzeau C, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med 2023;389:335–347. 10.1056/nejmoa2303379</cite> [<a href="https://doi.org/10.1056/NEJMoa2303379" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37272512/" class="usa-link">PubMed</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16. 10.1056/nejmoa2024850.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2024850" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33626253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Munshi%20NC,%20Anderson%20LD,%20Shah%20N,%20Madduri%20D,%20Berdeja%20J,%20Lonial%20S,%20Raje%20N,%20Lin%20Y,%20Siegel%20D,%20Oriol%20A,%20et%20al.%20Idecabtagene%20vicleucel%20in%20relapsed%20and%20refractory%20multiple%20myeloma.%20N%20Engl%20J%20Med.%202021;384:705%E2%80%9316.%2010.1056/nejmoa2024850." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers. 2023;15:1003. 10.3390/CANCERS15041003.
</cite> [<a href="https://doi.org/10.3390/cancers15041003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9954171/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36831349/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20V,%20Gauthier%20M,%20Decot%20V,%20Reppel%20L,%20Bensoussan%20D.%20Systematic%20review%20on%20CAR-T%20cell%20clinical%20trials%20up%20to%202022:%20academic%20center%20input.%20Cancers.%202023;15:1003.%2010.3390/CANCERS15041003." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Giavridis T, Van Der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731–8. 10.1038/s41591-018-0041-7.
</cite> [<a href="https://doi.org/10.1038/s41591-018-0041-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6410714/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29808005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Giavridis%20T,%20Van%20Der%20Stegen%20SJC,%20Eyquem%20J,%20Hamieh%20M,%20Piersigilli%20A,%20Sadelain%20M.%20CAR%20T%20cell%E2%80%93induced%20cytokine%20release%20syndrome%20is%20mediated%20by%20macrophages%20and%20abated%20by%20IL-1%20blockade.%20Nat%20Med.%202018;24:731%E2%80%938.%2010.1038/s41591-018-0041-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–48. 10.1038/S41591-018-0036-4.
</cite> [<a href="https://doi.org/10.1038/s41591-018-0036-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29808007/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Norelli%20M,%20Camisa%20B,%20Barbiera%20G,%20Falcone%20L,%20Purevdorj%20A,%20Genua%20M,%20Sanvito%20F,%20Ponzoni%20M,%20Doglioni%20C,%20Cristofori%20P,%20et%20al.%20Monocyte-derived%20IL-1%20and%20IL-6%20are%20differentially%20required%20for%20cytokine-release%20syndrome%20and%20neurotoxicity%20due%20to%20CAR%20T%20cells.%20Nat%20Med.%202018;24:739%E2%80%9348.%2010.1038/S41591-018-0036-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Nicolas Gonzalez Castro L, Herlopian A, Maus MV, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133:2212–21. 10.1182/blood-2018-12-893396.
</cite> [<a href="https://doi.org/10.1182/blood-2018-12-893396" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30808634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Karschnia%20P,%20Jordan%20JT,%20Forst%20DA,%20Arrillaga-Romany%20IC,%20Batchelor%20TT,%20Baehring%20JM,%20Clement%20NF,%20Nicolas%20Gonzalez%20Castro%20L,%20Herlopian%20A,%20Maus%20MV,%20et%20al.%20Clinical%20presentation,%20management,%20and%20biomarkers%20of%20neurotoxicity%20after%20adoptive%20immunotherapy%20with%20CAR%20T%20cells.%20Blood.%202019;133:2212%E2%80%9321.%2010.1182/blood-2018-12-893396." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Fajgenbaum DC, June CH. Cytokine Storm. 2020;383:2255–2273. 10.1056/NEJMRA2026131</cite> [<a href="https://doi.org/10.1056/NEJMra2026131" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7727315/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33264547/" class="usa-link">PubMed</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Brudno JN, Lam N, Vanasse D, Shen Y, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. 10.1038/s41591-019-0737-3</cite> [<a href="https://doi.org/10.1038/s41591-019-0737-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7781235/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31959992/" class="usa-link">PubMed</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–38. 10.1172/JCI85309.
</cite> [<a href="https://doi.org/10.1172/JCI85309" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4887159/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27111235/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Turtle%20CJ,%20Hanafi%20LA,%20Berger%20C,%20Gooley%20TA,%20Cherian%20S,%20Hudecek%20M,%20Sommermeyer%20D,%20Melville%20K,%20Pender%20B,%20Budiarto%20TM,%20et%20al.%20CD19%20CAR%E2%80%93T%20cells%20of%20defined%20CD4+:CD8+%20composition%20in%20adult%20B%20cell%20ALL%20patients.%20J%20Clin%20Invest.%202016;126:2123%E2%80%9338.%2010.1172/JCI85309." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016. 10.1126/scitranslmed.aaf8621.
</cite> [<a href="https://doi.org/10.1126/scitranslmed.aaf8621" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5045301/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27605551/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Turtle%20CJ,%20Hanafi%20LA,%20Berger%20C,%20Hudecek%20M,%20Pender%20B,%20Robinson%20E,%20Hawkins%20R,%20Chaney%20C,%20Cherian%20S,%20Chen%20X,%20et%20al.%20Immunotherapy%20of%20non-Hodgkin%E2%80%99s%20lymphoma%20with%20a%20defined%20ratio%20of%20CD8+%20and%20CD4+%20CD19-specific%20chimeric%20antigen%20receptor-modified%20T%20cells.%20Sci%20Transl%20Med.%202016.%2010.1126/scitranslmed.aaf8621." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood. 2017;130:2295–306. 10.1182/blood-2017-06-793141.
</cite> [<a href="https://doi.org/10.1182/blood-2017-06-793141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5701525/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28924019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hay%20KA,%20Hanafi%20LA,%20Li%20D,%20Gust%20J,%20Liles%20WC,%20Wurfel%20MM,%20L%C3%B3pez%20JA,%20Chen%20J,%20Chung%20D,%20Harju-Baker%20S,%20et%20al.%20Kinetics%20and%20biomarkers%20of%20severe%20cytokine%20release%20syndrome%20after%20CD19%20chimeric%20antigen%20receptor%E2%80%93modified%20T-cell%20therapy.%20Blood.%202017;130:2295%E2%80%93306.%2010.1182/blood-2017-06-793141." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404–19.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-17-0698" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5718945/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29025771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gust%20J,%20Hay%20KA,%20Hanafi%20LA,%20Li%20D,%20Myerson%20D,%20Gonzalez-Cuyar%20LF,%20Yeung%20C,%20Liles%20WC,%20Wurfel%20M,%20Lopez%20JA,%20et%20al.%20Endothelial%20activation%20and%20blood%E2%80%93brain%20barrier%20disruption%20in%20neurotoxicity%20after%20adoptive%20immunotherapy%20with%20CD19%20CAR-T%20cells.%20Cancer%20Discov.%202017;7:1404%E2%80%9319." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2022;28:294–302. 10.1016/J.JTCT.2022.03.006.
</cite> [<a href="https://doi.org/10.1016/j.jtct.2022.03.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9197870/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35288347/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grant%20SJ,%20Grimshaw%20AA,%20Silberstein%20J,%20Murdaugh%20D,%20Wildes%20TM,%20Rosko%20AE,%20Giri%20S.%20Clinical%20presentation,%20risk%20factors,%20and%20outcomes%20of%20immune%20effector%20cell-associated%20neurotoxicity%20syndrome%20following%20chimeric%20antigen%20receptor%20T%20cell%20therapy:%20a%20systematic%20review.%20Transplant%20Cell%20Ther.%202022;28:294%E2%80%93302.%2010.1016/J.JTCT.2022.03.006." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B. Dose-response correlation for CAR-T cells: a systematic review of clinical studies. J Immunother Cancer. 2022. 10.1136/JITC-2022-005678.
</cite> [<a href="https://doi.org/10.1136/jitc-2022-005678" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9791395/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36549782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rotte%20A,%20Frigault%20MJ,%20Ansari%20A,%20Gliner%20B,%20Heery%20C,%20Shah%20B.%20Dose-response%20correlation%20for%20CAR-T%20cells:%20a%20systematic%20review%20of%20clinical%20studies.%20J%20Immunother%20Cancer.%202022.%2010.1136/JITC-2022-005678." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Chohan KL, Siegler EL, Saad ·, Kenderian S. CART AND IMMUNOTHERAPY (M RUELLA AND P HANLEY, SECTION EDITORS) CAR-T cell therapy: the efficacy and toxicity balance. (2023) 18:9–18. 10.1007/s11899-023-00687-7</cite> [<a href="https://doi.org/10.1007/s11899-023-00687-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10505056/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36763238/" class="usa-link">PubMed</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Casucci M, Falcone L, Camisa B, Norelli M, Porcellini S, Stornaiuolo A, Ciceri F, Traversari C, Bordignon C, Bonini C, et al. Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional car-t cells co-expressing a suicide gene. Front Immunol. 2018;9: 329239. 10.3389/FIMMU.2018.00507/BIBTEX.</cite> [<a href="https://doi.org/10.3389/fimmu.2018.00507" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5871667/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29619024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Casucci%20M,%20Falcone%20L,%20Camisa%20B,%20Norelli%20M,%20Porcellini%20S,%20Stornaiuolo%20A,%20Ciceri%20F,%20Traversari%20C,%20Bordignon%20C,%20Bonini%20C,%20et%20al.%20Extracellular%20NGFR%20spacers%20allow%20efficient%20tracking%20and%20enrichment%20of%20fully%20functional%20car-t%20cells%20co-expressing%20a%20suicide%20gene.%20Front%20Immunol.%202018;9:%20329239.%2010.3389/FIMMU.2018.00507/BIBTEX." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Vitale C, Strati P. CAR T-cell therapy for B-cell non-hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;10: 532324. 10.3389/FONC.2020.00849/BIBTEX.</cite> [<a href="https://doi.org/10.3389/fonc.2020.00849" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7326110/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32670869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vitale%20C,%20Strati%20P.%20CAR%20T-cell%20therapy%20for%20B-cell%20non-hodgkin%20lymphoma%20and%20chronic%20lymphocytic%20leukemia:%20clinical%20trials%20and%20real-world%20experiences.%20Front%20Oncol.%202020;10:%20532324.%2010.3389/FONC.2020.00849/BIBTEX." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Sierro-Martínez B, Escamilla-Gómez V, Pérez-Ortega L, Guijarro-Albaladejo B, Hernández-Díaz P, de la Rosa-Garrido M, Lara-Chica M, Rodríguez-Gil A, Reguera-Ortega JL, Sanoja-Flores L, et al. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. Cell Oncol. 2024. 10.1007/S13402-024-00984-0.</cite> [<a href="https://doi.org/10.1007/s13402-024-00984-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11850460/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39192092/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sierro-Mart%C3%ADnez%20B,%20Escamilla-G%C3%B3mez%20V,%20P%C3%A9rez-Ortega%20L,%20Guijarro-Albaladejo%20B,%20Hern%C3%A1ndez-D%C3%ADaz%20P,%20de%20la%20Rosa-Garrido%20M,%20Lara-Chica%20M,%20Rodr%C3%ADguez-Gil%20A,%20Reguera-Ortega%20JL,%20Sanoja-Flores%20L,%20et%20al.%20Next-generation%20BCMA-targeted%20chimeric%20antigen%20receptor%20CARTemis-1:%20the%20impact%20of%20manufacturing%20procedure%20on%20CAR%20T-cell%20features.%20Cell%20Oncol.%202024.%2010.1007/S13402-024-00984-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Agostino MD, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma : can we do better? Leukemia. 2020. 10.1038/s41375-019-0669-4.
</cite> [<a href="https://doi.org/10.1038/s41375-019-0669-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31780814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Agostino%20MD,%20Raje%20N.%20Anti-BCMA%20CAR%20T-cell%20therapy%20in%20multiple%20myeloma%E2%80%AF:%20can%20we%20do%20better?%20Leukemia.%202020.%2010.1038/s41375-019-0669-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Porter DL, Hwang W-T, Frey N V, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <a href="http://www.ScienceTranslationalMedicine.org" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.ScienceTranslationalMedicine.org</a></cite> [<a href="https://doi.org/10.1126/scitranslmed.aac5415" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5909068/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26333935/" class="usa-link">PubMed</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–9. 10.1200/JCO.2014.56.2025.
</cite> [<a href="https://doi.org/10.1200/JCO.2014.56.2025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4322257/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25154820/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kochenderfer%20JN,%20Dudley%20ME,%20Kassim%20SH,%20Somerville%20RPT,%20Carpenter%20RO,%20Maryalice%20SS,%20Yang%20JC,%20Phan%20GQ,%20Hughes%20MS,%20Sherry%20RM,%20et%20al.%20Chemotherapy-refractory%20diffuse%20large%20B-cell%20lymphoma%20and%20indolent%20B-cell%20malignancies%20can%20be%20effectively%20treated%20with%20autologous%20T%20cells%20expressing%20an%20anti-CD19%20chimeric%20antigen%20receptor.%20J%20Clin%20Oncol.%202015;33:540%E2%80%939.%2010.1200/JCO.2014.56.2025." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014. 10.1126/scitranslmed.3008226.
</cite> [<a href="https://doi.org/10.1126/scitranslmed.3008226" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4684949/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24553386/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Davila%20ML,%20Riviere%20I,%20Wang%20X,%20Bartido%20S,%20Park%20J,%20Curran%20K,%20Chung%20SS,%20Stefanski%20J,%20Borquez-Ojeda%20O,%20Olszewska%20M,%20et%20al.%20Efficacy%20and%20toxicity%20management%20of%2019%E2%80%9328z%20CAR%20T%20cell%20therapy%20in%20B%20cell%20acute%20lymphoblastic%20leukemia.%20Sci%20Transl%20Med.%202014.%2010.1126/scitranslmed.3008226." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17. 10.1056/NEJMoa1407222.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1407222" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4267531/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25317870/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Maude%20SL,%20Frey%20N,%20Shaw%20PA,%20Aplenc%20R,%20Barrett%20DM,%20Bunin%20NJ,%20Chew%20A,%20Gonzalez%20VE,%20Zheng%20Z,%20Lacey%20SF,%20et%20al.%20Chimeric%20antigen%20receptor%20T%20cells%20for%20sustained%20remissions%20in%20leukemia.%20N%20Engl%20J%20Med.%202014;371:1507%E2%80%9317.%2010.1056/NEJMoa1407222." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Majdoul S, Seye AK, Kichler A, Holic N, Galy A, Bechinger B, Fenard D. Molecular determinants of vectofusin-1 and its derivatives for the enhancement of lentivirally mediated gene transfer into hematopoietic stem/progenitor cells. J Biol Chem. 2016;291:2161–9. 10.1074/JBC.M115.675033.
</cite> [<a href="https://doi.org/10.1074/jbc.M115.675033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4732202/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26668323/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Majdoul%20S,%20Seye%20AK,%20Kichler%20A,%20Holic%20N,%20Galy%20A,%20Bechinger%20B,%20Fenard%20D.%20Molecular%20determinants%20of%20vectofusin-1%20and%20its%20derivatives%20for%20the%20enhancement%20of%20lentivirally%20mediated%20gene%20transfer%20into%20hematopoietic%20stem/progenitor%20cells.%20J%20Biol%20Chem.%202016;291:2161%E2%80%939.%2010.1074/JBC.M115.675033." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Jamali A, Kapitza L, Schaser T, Johnston ICD, Buchholz CJ, Hartmann J. Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors. Mol Ther Methods Clin Dev. 2019;13:371–9. 10.1016/J.OMTM.2019.03.003.
</cite> [<a href="https://doi.org/10.1016/j.omtm.2019.03.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6453803/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30997367/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jamali%20A,%20Kapitza%20L,%20Schaser%20T,%20Johnston%20ICD,%20Buchholz%20CJ,%20Hartmann%20J.%20Highly%20efficient%20and%20selective%20CAR-gene%20transfer%20using%20CD4-%20and%20CD8-targeted%20lentiviral%20vectors.%20Mol%20Ther%20Methods%20Clin%20Dev.%202019;13:371%E2%80%939.%2010.1016/J.OMTM.2019.03.003." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–9. 10.1038/ni.2035.
</cite> [<a href="https://doi.org/10.1038/ni.2035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21739672/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wherry%20EJ.%20T%20cell%20exhaustion.%20Nat%20Immunol.%202011;12:492%E2%80%939.%2010.1038/ni.2035." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Ma J, Yan S, Zhao Y, Yan H, Zhang Q, Li X. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells. Front Immunol. 2023;14:1265255. 10.3389/FIMMU.2023.1265255/BIBTEX.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1265255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10568325/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37841254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ma%20J,%20Yan%20S,%20Zhao%20Y,%20Yan%20H,%20Zhang%20Q,%20Li%20X.%20Blockade%20of%20PD-1%20and%20LAG-3%20expression%20on%20CD8+%20T%20cells%20promotes%20the%20tumoricidal%20effects%20of%20CD8+%20T%20cells.%20Front%20Immunol.%202023;14:1265255.%2010.3389/FIMMU.2023.1265255/BIBTEX." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>SD Blackburn HSGFEW. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc Natl Acad Sci USA. 2008;105:15016–21.
</cite> [<a href="https://doi.org/10.1073/pnas.0801497105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2567485/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18809920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?SD%20Blackburn%20HSGFEW.%20Selective%20expansion%20of%20a%20subset%20of%20exhausted%20CD8%20T%20cells%20by%20%CE%B1PD-L1%20blockade.%20Proc%20Natl%20Acad%20Sci%20USA.%202008;105:15016%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138:30–50. 10.1016/J.CELL.2009.06.036.
</cite> [<a href="https://doi.org/10.1016/j.cell.2009.06.036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19596234/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Virgin%20HW,%20Wherry%20EJ,%20Ahmed%20R.%20Redefining%20chronic%20viral%20infection.%20Cell.%202009;138:30%E2%80%9350.%2010.1016/J.CELL.2009.06.036." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581–90. 10.1038/nm.3838.
</cite> [<a href="https://doi.org/10.1038/nm.3838" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4458184/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25939063/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Long%20AH,%20Haso%20WM,%20Shern%20JF,%20Wanhainen%20KM,%20Murgai%20M,%20Ingaramo%20M,%20Smith%20JP,%20Walker%20AJ,%20Kohler%20ME,%20Venkateshwara%20VR,%20et%20al.%204%E2%80%931BB%20costimulation%20ameliorates%20T%20cell%20exhaustion%20induced%20by%20tonic%20signaling%20of%20chimeric%20antigen%20receptors.%20Nat%20Med.%202015;21:581%E2%80%9390.%2010.1038/nm.3838." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Ajina A, Maher J. Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther. 2018;17:1795–815. 10.1158/1535-7163.MCT-17-1097.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-17-1097" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6130819/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30181329/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ajina%20A,%20Maher%20J.%20Strategies%20to%20address%20chimeric%20antigen%20receptor%20tonic%20signaling.%20Mol%20Cancer%20Ther.%202018;17:1795%E2%80%93815.%2010.1158/1535-7163.MCT-17-1097." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Rodriguez-Marquez P, Calleja-Cervantes ME, Serrano G, Oliver-Caldes A, Palacios-Berraquero ML, Martin-Mallo A, Calviño C, Español-Rego M, Ceballos C, Lozano T, et al. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. Sci Adv. 2022;8:514.</cite> [<a href="https://doi.org/10.1126/sciadv.abo0514" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9524842/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36179026/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rodriguez-Marquez%20P,%20Calleja-Cervantes%20ME,%20Serrano%20G,%20Oliver-Caldes%20A,%20Palacios-Berraquero%20ML,%20Martin-Mallo%20A,%20Calvi%C3%B1o%20C,%20Espa%C3%B1ol-Rego%20M,%20Ceballos%20C,%20Lozano%20T,%20et%20al.%20CAR%20density%20influences%20antitumoral%20efficacy%20of%20BCMA%20CAR%20T%20cells%20and%20correlates%20with%20clinical%20outcome.%20Sci%20Adv.%202022;8:514." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Kaminski J, Fleming RA, Alvarez-Calderon F, Winschel MB, McGuckin C, Ho EE, Eng F, Rui X, Keskula P, Cagnin L, et al. B-cell-directed CAR-T cell therapy activates CD8+ cytotoxic CARneg bystander T-cells in non-human primates and patients. Blood. 2024. 10.1182/BLOOD.2023022717.
</cite> [<a href="https://doi.org/10.1182/blood.2023022717" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11561542/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38558106/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kaminski%20J,%20Fleming%20RA,%20Alvarez-Calderon%20F,%20Winschel%20MB,%20McGuckin%20C,%20Ho%20EE,%20Eng%20F,%20Rui%20X,%20Keskula%20P,%20Cagnin%20L,%20et%20al.%20B-cell-directed%20CAR-T%20cell%20therapy%20activates%20CD8+%20cytotoxic%20CARneg%20bystander%20T-cells%20in%20non-human%20primates%20and%20patients.%20Blood.%202024.%2010.1182/BLOOD.2023022717." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Chen PH, Lipschitz M, Weirather JL, Jacobson C, Armand P, Wright K, Hodi FS, Roberts ZJ, Sievers SA, Rossi J, et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020. 10.1172/JCI.INSIGHT.134612.
</cite> [<a href="https://doi.org/10.1172/jci.insight.134612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7406247/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32484797/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20PH,%20Lipschitz%20M,%20Weirather%20JL,%20Jacobson%20C,%20Armand%20P,%20Wright%20K,%20Hodi%20FS,%20Roberts%20ZJ,%20Sievers%20SA,%20Rossi%20J,%20et%20al.%20Activation%20of%20CAR%20and%20non-CAR%20T%20cells%20within%20the%20tumor%20microenvironment%20following%20CAR%20T%20cell%20therapy.%20JCI%20Insight.%202020.%2010.1172/JCI.INSIGHT.134612." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Lee W, Rose D, Keck JG, Yang J. Abstract 3850: Modeling individual variability in CD19 CAR-T therapy: an in vivo study with PBMC-humanized mice. Cancer Res. 2024;84:3850–3850. 10.1158/1538-7445.AM2024-3850.</cite> [<a href="https://scholar.google.com/scholar_lookup?Lee%20W,%20Rose%20D,%20Keck%20JG,%20Yang%20J.%20Abstract%203850:%20Modeling%20individual%20variability%20in%20CD19%20CAR-T%20therapy:%20an%20in%20vivo%20study%20with%20PBMC-humanized%20mice.%20Cancer%20Res.%202024;84:3850%E2%80%933850.%2010.1158/1538-7445.AM2024-3850." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Louie RHY, Cai C, Samir J, Singh M, Deveson IW, Ferguson JM, Amos TG, McGuire HM, Gowrishankar K, Adikari T, et al. CAR+ and CAR−T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies. Nat Commun. 2023;14:1–18. 10.1038/s41467-023-43656-7.
</cite> [<a href="https://doi.org/10.1038/s41467-023-43656-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10682404/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38012187/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Louie%20RHY,%20Cai%20C,%20Samir%20J,%20Singh%20M,%20Deveson%20IW,%20Ferguson%20JM,%20Amos%20TG,%20McGuire%20HM,%20Gowrishankar%20K,%20Adikari%20T,%20et%20al.%20CAR+%20and%20CAR%E2%88%92T%20cells%20share%20a%20differentiation%20trajectory%20into%20an%20NK-like%20subset%20after%20CD19%20CAR%20T%20cell%20infusion%20in%20patients%20with%20B%20cell%20malignancies.%20Nat%20Commun.%202023;14:1%E2%80%9318.%2010.1038/s41467-023-43656-7." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity. 2011;35:972–85. 10.1016/J.IMMUNI.2011.09.019.
</cite> [<a href="https://doi.org/10.1016/j.immuni.2011.09.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3246082/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22177921/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Muranski%20P,%20Borman%20ZA,%20Kerkar%20SP,%20Klebanoff%20CA,%20Ji%20Y,%20Sanchez-Perez%20L,%20Sukumar%20M,%20Reger%20RN,%20Yu%20Z,%20Kern%20SJ,%20et%20al.%20Th17%20cells%20are%20long%20lived%20and%20retain%20a%20stem%20cell-like%20molecular%20signature.%20Immunity.%202011;35:972%E2%80%9385.%2010.1016/J.IMMUNI.2011.09.019." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM1_ESM.docx</a><sup> (811.8KB, docx) </sup><p>Supplementary Material 1. Supplementary Figures.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM2_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM2_ESM.pdf</a><sup> (121.3KB, pdf) </sup><p>Supplementary Material 2. Supplementary Table 1.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM3_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM3_ESM.pdf</a><sup> (360.9KB, pdf) </sup><p>Supplementary Material 3. Supplementary Table 2.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM4_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM4_ESM.pdf</a><sup> (98.4KB, pdf) </sup><p>Supplementary Material 4. Supplementary Table 3.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366063/bin/12967_2025_6899_MOESM5_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">12967_2025_6899_MOESM5_ESM.pdf</a><sup> (100.3KB, pdf) </sup><p>Supplementary Material 5. Supplementary Table 4</p>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data generated in this study is available upon request to the corresponding author.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Translational Medicine are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12967-025-06899-0"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12967_2025_Article_6899.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.7 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12366063/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12366063/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366063%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366063/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12366063/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12366063/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830482/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12366063/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830482/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12366063/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12366063/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="NUu7q0toLpulwe8AqRzzZVazv1VWA4sbZy5WJxj9UomdaDmwYii2fJYwfnceTHlj">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
